Achmea Investment Management B.V. Trims Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Achmea Investment Management B.V. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 85.0% during the fourth quarter, Holdings Channel reports. The firm owned 2,816 shares of the company’s stock after selling 15,974 shares during the quarter. Achmea Investment Management B.V.’s holdings in IDEXX Laboratories were worth $1,164,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of IDXX. Aptus Capital Advisors LLC boosted its position in IDEXX Laboratories by 19.4% during the 3rd quarter. Aptus Capital Advisors LLC now owns 629 shares of the company’s stock valued at $318,000 after acquiring an additional 102 shares in the last quarter. Huntington National Bank boosted its position in IDEXX Laboratories by 1.1% during the 3rd quarter. Huntington National Bank now owns 3,979 shares of the company’s stock valued at $2,010,000 after acquiring an additional 42 shares in the last quarter. Impax Asset Management Group plc boosted its position in IDEXX Laboratories by 14.7% during the 3rd quarter. Impax Asset Management Group plc now owns 8,655 shares of the company’s stock valued at $4,373,000 after acquiring an additional 1,110 shares in the last quarter. CIBC Asset Management Inc boosted its position in IDEXX Laboratories by 5.5% during the 3rd quarter. CIBC Asset Management Inc now owns 25,578 shares of the company’s stock valued at $12,923,000 after acquiring an additional 1,338 shares in the last quarter. Finally, Empirical Finance LLC boosted its position in IDEXX Laboratories by 2.3% during the 3rd quarter. Empirical Finance LLC now owns 2,887 shares of the company’s stock valued at $1,459,000 after acquiring an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IDXX. Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Finally, Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $415.30 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The firm has a market cap of $33.78 billion, a P/E ratio of 38.92, a PEG ratio of 3.41 and a beta of 1.39. The company has a 50 day moving average of $438.03 and a 200 day moving average of $447.00. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.18% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.